Onconetix, Inc. Comprehensive Income
Onconetix, Inc. (ONCO) reported Comprehensive Income of -$2.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$2.99M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$4.43M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $6.33M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$8.95M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$11.20M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$63.80M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$35.03M.
- Onconetix, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$13.42M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.99M 10-Q · filed 2026-08-13 | -$7.42M 10-Q · filed 2026-08-13 | -$1.09M derived: sum of 3 quarters · filed 2026-08-13 | -$10.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$4.43M 10-Q · filed 2026-05-13 | $1.90M derived: sum of 2 quarters · filed 2026-05-13 | -$7.04M derived: sum of 3 quarters · filed 2026-05-13 | -$7.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$2.62M derived: sum of 2 quarters · filed 2026-03-13 | -$2.76M derived: sum of 3 quarters · filed 2026-08-13 | -$11.20M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$8.95M 10-Q · filed 2025-11-13 | -$9.09M derived: sum of 2 quarters · filed 2026-08-13 | -$17.53M 10-Q · filed 2025-11-13 | -$50.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$144.66K 10-Q · filed 2026-08-13 | -$8.58M 10-Q · filed 2026-08-13 | -$41.75M derived: sum of 3 quarters · filed 2026-08-13 | -$42.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$8.44M 10-Q · filed 2026-05-13 | -$41.61M derived: sum of 2 quarters · filed 2026-05-13 | -$42.05M derived: sum of 3 quarters · filed 2026-05-13 | -$56.28M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$33.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$33.61M derived: sum of 2 quarters · filed 2026-03-13 | -$47.84M derived: sum of 3 quarters · filed 2026-03-13 | -$63.80M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$435.90K 10-Q · filed 2025-11-13 | -$14.67M derived: sum of 2 quarters · filed 2025-11-13 | -$30.62M 10-Q · filed 2025-11-13 | -$50.59M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$14.23M 10-Q · filed 2025-08-14 | -$30.19M 10-Q · filed 2025-08-14 | -$50.16M derived: sum of 3 quarters · filed 2025-08-14 | -$55.50M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$15.96M 10-Q · filed 2025-06-12 | -$35.92M derived: sum of 2 quarters · filed 2025-06-12 | -$41.27M derived: sum of 3 quarters · filed 2025-06-12 | -$48.14M derived: sum of 4 quarters · filed 2025-06-12 |
| 2023-12-31 | -$19.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -$25.32M derived: sum of 2 quarters · filed 2025-06-02 | -$32.18M derived: sum of 3 quarters · filed 2025-06-02 | -$35.03M 10-K · filed 2025-06-02 |
| 2023-09-30 | -$5.35M 10-Q · filed 2024-12-10 | -$12.21M derived: sum of 2 quarters · filed 2024-12-10 | -$15.06M 10-Q · filed 2024-12-10 | |
| 2023-06-30 | -$6.87M 10-Q · filed 2024-08-29 | -$9.71M 10-Q · filed 2024-08-29 | ||
| 2023-03-31 | -$2.85M 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | -$13.42M 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |